T1	Outcomes 1008 1043	median number of aflibercept cycles
T2	Outcomes 1139 1170	were neutropenia (37%), fatigue
T3	Outcomes 1177 1193	and hypertension
T4	Outcomes 1339 1348	patients.
T5	Outcomes 1349 1428	Plasma levels of free over vascular endothelial growth factor-bound aflibercept
